Interstitial pneumonia induced by cyclophosphamide: A case report and review of the literature

Introduction: Recently, interstitial lung disease significantly increases and it is difficult to treat. Cyclophosphamide(CP) is one drug administrated in interstitial lung disease, which can also cause pulmonary fibrosis and lung function lesion. This article present a case which exacerbated interst...

Full description

Bibliographic Details
Main Authors: Panpan Qian, Chun hong Peng, Xianwei Ye
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Respiratory Medicine Case Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007118303009
id doaj-42b7e7618300401ea572a0de84a162b9
record_format Article
spelling doaj-42b7e7618300401ea572a0de84a162b92020-11-24T23:49:10ZengElsevierRespiratory Medicine Case Reports2213-00712019-01-0126212214Interstitial pneumonia induced by cyclophosphamide: A case report and review of the literaturePanpan Qian0Chun hong Peng1Xianwei Ye2ZunYi Medical University, Zunyi, Guizhou Province, China; Department of Respiration and Critical Care Medicine, Guizhou Provincial People's Hospital, Guiyang, Guizhou Province, ChinaDepartment of Respiration and Critical Care Medicine, Guizhou Provincial People's Hospital, Guiyang, Guizhou Province, ChinaDepartment of Respiration and Critical Care Medicine, Guizhou Provincial People's Hospital, Guiyang, Guizhou Province, China; Corresponding author. Department of Respiration and Critical Care Medicine, Guizhou Provincial People's Hospital, 83 Zhongshan East Road, Guiyang City, Guizhou Province, China.Introduction: Recently, interstitial lung disease significantly increases and it is difficult to treat. Cyclophosphamide(CP) is one drug administrated in interstitial lung disease, which can also cause pulmonary fibrosis and lung function lesion. This article present a case which exacerbated interstitial pneumonia after treatment by CP, aiming to enhance the understanding of the side effects of CP and standardize usage of the CP. Case presentation: A patient of nephrotic syndrome administrated with CP suffered respiratory insufficiency requiring mechanical ventilation. Computed tomography (CT) imaging was compatible with interstitial pneumonia(IP). After treating with multimodal combination therapy (corticosteroids, immune globulins), the patient survived. The clinical characteristics of CP-related lung toxicity and/or pulmonary fibrosis should be paid more attention to avoid the serious outcomes. Conclusion: Although interstitial lung disease induced by CP is rare, with the current widespread usage of CP increases the risks of diffuse interstitial pneumonia and pulmonary fibrosis, which need to be noted in time to get early treatment. Keywords: Side effect, Interstitial pneumonia, Toxicity, Cyclophosphamidehttp://www.sciencedirect.com/science/article/pii/S2213007118303009
collection DOAJ
language English
format Article
sources DOAJ
author Panpan Qian
Chun hong Peng
Xianwei Ye
spellingShingle Panpan Qian
Chun hong Peng
Xianwei Ye
Interstitial pneumonia induced by cyclophosphamide: A case report and review of the literature
Respiratory Medicine Case Reports
author_facet Panpan Qian
Chun hong Peng
Xianwei Ye
author_sort Panpan Qian
title Interstitial pneumonia induced by cyclophosphamide: A case report and review of the literature
title_short Interstitial pneumonia induced by cyclophosphamide: A case report and review of the literature
title_full Interstitial pneumonia induced by cyclophosphamide: A case report and review of the literature
title_fullStr Interstitial pneumonia induced by cyclophosphamide: A case report and review of the literature
title_full_unstemmed Interstitial pneumonia induced by cyclophosphamide: A case report and review of the literature
title_sort interstitial pneumonia induced by cyclophosphamide: a case report and review of the literature
publisher Elsevier
series Respiratory Medicine Case Reports
issn 2213-0071
publishDate 2019-01-01
description Introduction: Recently, interstitial lung disease significantly increases and it is difficult to treat. Cyclophosphamide(CP) is one drug administrated in interstitial lung disease, which can also cause pulmonary fibrosis and lung function lesion. This article present a case which exacerbated interstitial pneumonia after treatment by CP, aiming to enhance the understanding of the side effects of CP and standardize usage of the CP. Case presentation: A patient of nephrotic syndrome administrated with CP suffered respiratory insufficiency requiring mechanical ventilation. Computed tomography (CT) imaging was compatible with interstitial pneumonia(IP). After treating with multimodal combination therapy (corticosteroids, immune globulins), the patient survived. The clinical characteristics of CP-related lung toxicity and/or pulmonary fibrosis should be paid more attention to avoid the serious outcomes. Conclusion: Although interstitial lung disease induced by CP is rare, with the current widespread usage of CP increases the risks of diffuse interstitial pneumonia and pulmonary fibrosis, which need to be noted in time to get early treatment. Keywords: Side effect, Interstitial pneumonia, Toxicity, Cyclophosphamide
url http://www.sciencedirect.com/science/article/pii/S2213007118303009
work_keys_str_mv AT panpanqian interstitialpneumoniainducedbycyclophosphamideacasereportandreviewoftheliterature
AT chunhongpeng interstitialpneumoniainducedbycyclophosphamideacasereportandreviewoftheliterature
AT xianweiye interstitialpneumoniainducedbycyclophosphamideacasereportandreviewoftheliterature
_version_ 1725483746364227584